U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H35N5O5
Molecular Weight 581.6615
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERGOTAMINE

SMILES

[H][C@@]12CCCN1C(=O)[C@H](CC3=CC=CC=C3)N4C(=O)[C@](C)(NC(=O)[C@H]5CN(C)[C@]6([H])CC7=CNC8=C7C(=CC=C8)C6=C5)O[C@@]24O

InChI

InChIKey=XCGSFFUVFURLIX-VFGNJEKYSA-N
InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1

HIDE SMILES / InChI

Description

The isolation and naming of ergotamine by Stoll occurred in 1925 but the complete elucidation of structure was not achieved until 1951, with synthesis following some 10 years later. Current sources of ergotamine include the isolation from field ergot and fermentation broth, as well as synthesis via coupling of (+)-lysergic acid with the appropriate synthetic peptidic moiety. Ergotamine was introduced into world commerce in 1921, and is currently marketed as its water soluble tartrate salt. Ergotamine is a partial agonist at various tryptaminergic receptors (including the serotonin receptor [5-HT2]) and at various α-adrenergic receptors in blood vessels and various smooth muscles. It is likely that the major activity of ergotamine and related alkaloids is one of agonism at the 5-HT1B/1D receptors, just as with the “triptan” antimigraine compounds. FDA-labeled indications for ergotamine tartrate are in the abortion or prevention of vascular headaches, such as migraine, migraine variant, cluster headache, and histaminic cephalalgia.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.34 nM [Ki]
5.4 nM [Ki]
0.4 nM [Ki]
9.4 nM [Ki]
3.0 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ERGOMAR
Primary
CAFERGOT
Primary
MIGERGOT

Cmax

ValueDoseCo-administeredAnalytePopulation
454 pg/mL
2 mg single, rectal
ERGOTAMINE plasma
Homo sapiens
21.4 pg/mL
2 mg single, oral
ERGOTAMINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1216 pg × h/mL
2 mg single, rectal
ERGOTAMINE plasma
Homo sapiens
61 pg × h/mL
2 mg single, oral
ERGOTAMINE plasma
Homo sapiens
4.38 ng × h/mL
3.89 μg/kg bw single, intravenous
ERGOTAMINE plasma
Homo sapiens
2.04 ng × h/mL
1.94 μg/kg bw single, intravenous
ERGOTAMINE plasma
Homo sapiens
1.36 ng × h/mL
1.01 μg/kg bw single, intravenous
ERGOTAMINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
3.35 h
2 mg single, rectal
ERGOTAMINE plasma
Homo sapiens
2.15 h
3.89 μg/kg bw single, intravenous
ERGOTAMINE plasma
Homo sapiens
2.13 h
1.94 μg/kg bw single, intravenous
ERGOTAMINE plasma
Homo sapiens
2.08 h
1.01 μg/kg bw single, intravenous
ERGOTAMINE plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as victim

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
MIGERGOT - ergotamine tartrate and caffeine rectal suppository. One suppository at start of attack; second suppository after 1 hour, if needed for full relief. Two suppositories is the maximum dose for an individual attack. Cafergot (Ergotamine tartrate 1 mg and Caffeine 100 mg Tablets) First attack: The first time Cafergot is taken, an initial dose of 2 Cafergot tablets orally, is recommended. If relief is not obtained within half an hour, a further tablet should be administered; this may be repeated at half-hourly intervals, but the maximum daily dose of 6 tablets should not be exceeded. Subsequent attacks: If the pain persists, take 1 tablet every half an hour up to the maximum daily dose of 6 tablets. The maximum weekly dose is 10 tablets. ERGOMAR SUBLINGUAL- ergotamine tartrate tablet For best results, dosage should start at the first sign of an attack. Early Administration Gives Maximum Effectiveness. At the first sign of an attack or to relieve symptoms after onset of an attack, one 2 mg tablet is placed under the tongue. Another tablet should be taken at half-hour intervals thereafter, if necessary, but dosage must not exceed three tablets in any 24hour period. Total weekly dosage should not exceed five tablets (10 mg) in any one week. Ergomar® Sublingual Tablets should not be used for chronic daily administration.
Route of Administration: Other
In Vitro Use Guide
The bovine anterior pituitary cells were implanted on culture tubes using D-valine minimal essential medium with serum to suppress the overgrowth of fibroblasts and then maintained in L-valine Dulbecco's modified Eagle medium. (3H)-Uridine uptake by these cells was suppressed by ergotamine at a concentration varing from 1-10 uM